Development and characterization of novel highly-loaded itraconazole poly(butyl cyanoacrylate) polymeric nanoparticles

Ćurić, Anamarija; Möschwitzer, Jan P.; Fricker, Gert

doi:10.1016/j.ejpb.2017.01.014

Cited by 32 publications

(8 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…ITC and its derivative compound POS, both triazole agents, are acceptable alternatives for treatment of the pulmonary form of cryptococcosis, but not for cryptococcal meningitis due to its difficulty of crossing the BBB [9].ĆURIĆ and contributors developed poly(butyl cyanoacrylate) nanoparticles for ITC [113], and demonstrated that nanoparticles functionalization with covalent binding of apolipoprotein E enabled targeting of low-density lipoprotein receptor (LDLR) expressed on the endothelial brain capillary cell membrane [114]. ITC was also incorporated in bovine serum albumin nanoparticles (ITC-BSA-NP) modified with borneol (BO) and polyethylene glycol (PEG) (PEG/BO-ITC-BSA-NP) [115].…”

Section: Drug Delivery Systemsmentioning

confidence: 99%

New Approaches for Cryptococcosis Treatment

et al. 2020

View full text Add to dashboard Cite

Cryptococcosis is an important opportunistic infection and a leading cause of meningitis in patients with HIV infection. The antifungal pharmacological treatment is limited to amphotericin B, fluconazole and 5- flucytosine. In addition to the limited pharmacological options, the high toxicity, increased resistance rate and difficulty of the currently available antifungal molecules to cross the blood–brain barrier hamper the treatment. Thus, the search for new alternatives for the treatment of cryptococcal meningitis is extremely necessary. In this review, we describe the therapeutic strategies currently available, discuss new molecules with antifungal potential in different phases of clinical trials and in advanced pre-clinical phase, and examine drug nanocarriers to improve delivery to the central nervous system.

show abstract

Section: Drug Delivery Systemsmentioning

confidence: 99%

New Approaches for Cryptococcosis Treatment

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Patients are treated with a combination of amphotericin B (alternatively: AmBisome), flucytosine and fluconazole until CSF tests are negative for Cryptococcal antigen; then follows maintenance treatment with fluconazole; special dosage forms of the antifungal agents help to improve the prognosis [33].…”

Section: Cryptococcus Neoformans Sppmentioning

confidence: 99%

Update Opportunistic Infections of the Central Nervous System in Patients with Iatrogenic Immunosuppression

Arendt

Maschke

2017

Neurology International Open

View full text Add to dashboard Cite

Opportunistic infections of the central nervous system (CNS) with bacteria, parasites, fungi or viruses due to iatrogenic immunosuppression are of immense importance because of rising numbers of organ transplantations and immunomodulating treatments. Besides transplantation medicine, the most frequently involved medical subspecialties are dermatology (interferons, rituximab, fingolimod, among others), hematology/oncology (rituximab, among others), neurology (beta-interferon, glatiramer acetate, natalizumab, rituximab, teriflunomide, fingolimod, alemtuzumab, daclizumab, among others) and rheumatology (rituximab).In Europe, typical infections affecting the immunocompromised host are due to herpes viruses and, especially in immunomodulated patients, JC virus (JCV); frequently occurring fungi are Aspergillus fumigatus, Candida albicans and Cryptococcus neoformans. An important parasite is Toxoplasma gondii (TG). Typical bacterial infections of the immunocompromised patient are caused by Nocardia asteroides, Listeria monocytogenes and Mycobacterium tuberculosis.Modern diagnostic and therapeutic procedures will be described.

show abstract

“…Die Therapie wird mit einer Kombination aus Amphotericin B (alternativ: Ambisome), Flucytosin und Fluconazol bis zur Antigen-Negativität im Liquor geführt, danach meist mit Fluconazol als Erhaltungstherapie, wobei spezielle Darreichungsformen der Antimykotika die Prognose verbessern [33].…”

Section: Cryptococcus Neoformans Sppunclassified

Neues zu opportunistischen Infektionen des zentralen Nervensystems bei iatrogener Immunsuppression

Arendt

Maschke

2017

Akt Neurol

View full text Add to dashboard Cite

ZusammenfassungOpportunistische Infektionen des zentralen Nervensystems (ZNS) mit infolge einer iatrogenen Immunsuppression auftretenden Virus-, Parasiten-, Pilz- oder Bakterien-induzierten Erkrankungen sind bei der steigenden Zahl an Patienten mit Organtransplantationen oder immunmodulierenden Therapien von großer medizinischer Bedeutung. Hauptsächliche Anwender dieser modernen Behandlungsformen sind neben der Transplantationsmedizin die Dermatologie (Interferone, Rituximab, Fingolimod u. a.), Hämato-/Onkologie (Rituximab u. a.), Neurologie (Beta-Interferon, Glatirameracetat, Natalizumab, Rituximab, Teriflunomid, Fingolimod, Alemtuzumab, Daclizumab u. a.) und Rheumatologie (Rituximab u. a.).Das Keimspektrum bei iatrogener Immunsuppression in Europa umfasst in der Hauptsache Viren der Herpesgruppe sowie insbesondere bei immunmodulatorisch behandelten Patienten das JC-Virus (JCV); an Pilzerregern sind Aspergillus fumigatus, Candida albicans und Cryptococcus neoformans von Bedeutung. Eine wichtige parasitäre Infektion ist die mit Toxoplasma gondii (T. g.). Typische bakterielle Infektionen des iatrogen immunkompromittierten Patienten werden durch Nocardia asteroides, Listeria monocytogenes und Mycobacterium tuberculosis hervorgerufen.Es werden typische diagnostische Konstellationen und Therapien vorgestellt.

show abstract

Development and characterization of novel highly-loaded itraconazole poly(butyl cyanoacrylate) polymeric nanoparticles

Cited by 32 publications

References 26 publications

New Approaches for Cryptococcosis Treatment

New Approaches for Cryptococcosis Treatment

Update Opportunistic Infections of the Central Nervous System in Patients with Iatrogenic Immunosuppression

Neues zu opportunistischen Infektionen des zentralen Nervensystems bei iatrogener Immunsuppression

Contact Info

Product

Resources

About